Acadia Pharmaceuticals (ACAD) Interest Expenses (2011 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Interest Expenses of $5.9 million for Q1 2026, down 90.75% year-over-year from $64.0 million in Q1 2025, and up 85.22% quarter-over-quarter from $3.2 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Interest Expenses (2011 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Interest Expenses history runs 16 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- In Q1 2026, Interest Expenses fell 90.75% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 90.75% YoY), while the FY2025 annual figure was $79.3 million, up 275.21% from the prior year.
- Interest Expenses for Q1 2026 stood at $5.9 million, up from $3.2 million in the prior quarter.
- The five-year high for Interest Expenses was $71.4 million in Q1 2023, with the low at $2.4 million in Q4 2022.
- The 5-year median for Interest Expenses is $9.9 million (2024), against an average of $21.7 million.
- The sharpest annual moves came in 2023 and 2026: Interest Expenses jumped 689.51% in 2023, then plunged 90.75% in 2026.
- Acadia Pharmaceuticals' Interest Expenses stood at $2.4 million in 2022, then advanced by 1.4% to $2.4 million in 2023, then gained by 7.52% to $2.6 million in 2024, then increased by 24.05% to $3.2 million in 2025, then surged by 85.22% to $5.9 million in 2026.
- Business Quant data shows ACAD's Interest Expenses at $5.9 million in Q1 2026, $3.2 million in Q4 2025, and $11.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 93.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 93.29 Mn |
| Jun 30, 2026 | 93.29 Mn |
| Mar 31, 2026 | 5.91 Mn |
| Mar 31, 2026 | 5.91 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 11.41 Mn |
| Sep 30, 2025 | 11.41 Mn |
| Jun 30, 2025 | 11.19 Mn |
| Jun 30, 2025 | 11.19 Mn |
| Mar 31, 2025 | 63.97 Mn |
| Mar 31, 2025 | 63.97 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 9.94 Mn |
| Jun 30, 2024 | 9.94 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Mar 31, 2024 | 9.94 Mn |